Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States

Because psychedelic-assisted therapy (PAT) is likely to be provided by interdisciplinary professional teams comprised of social workers, psychologists, and psychiatrists, understanding the acceptability of this treatment approach among these professional disciplines is essential as the treatment advances through approval processes at the Food and Drug Administration.The study includes data from three separate survey studies investigating the attitudes and beliefs about PAT among national samples of social workers (n = 309), psychiatrists (n = 181), and psychologists (n = 366). The combined sample (n = 856) was predominantly female (64.3%), with a mean age of 49 (SD = 16.13), and 17 (SD = 13.56) years of professional experience.There were no significant differences between groups in confidence that PAT would be effective. However, there were significant between-group differences in psychiatrists' understanding of PAT compared to social workers. Next, psychologists' mean ratings of the acceptability of PAT were significantly greater than social workers' ratings. Mean ratings about believing that PAT was a reasonable treatment approach were higher among psychologists compared to social workers and psychiatrists. Additionally, mean ratings regarding the disadvantages of PAT were significantly greater among social workers compared to psychologists and psychiatrists. Lastly, social workers' ratings that PAT could permanently improve clients' lives were significantly lower than psychiatrists and psychologists.Findings help elucidate overall impressions of PAT among disciplines likely involved in providing this treatment should it be approved and suggest the need for education and training across professions. However, given the inconsistencies across disciplines, more research is needed to inform successful interdisciplinary training programs and better understand potential barriers to dissemination of this new treatment.